Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

71.61 +0.48 (+0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,059,134
Open 71.70
Bid (Size) 68.00 (10)
Ask (Size) 81.70 (1)
Prev. Close 71.13
Today's Range 70.87 - 73.18
52wk Range 61.28 - 101.24
Shares Outstanding 87,500,961
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: 
Via Benzinga
Sarepta Therapeutics: Q1 Earnings Insights
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-20.80%
-20.80%
1 Month
-6.64%
-6.64%
3 Month
-4.57%
-4.57%
6 Month
-8.59%
-8.59%
1 Year
-7.25%
-7.25%

More News

Read More
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Sarepta Therapeutics's Earnings: A Preview
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership
Via Benzinga
Analyst Ratings For Sarepta Therapeutics
Via Benzinga
Expert Ratings For Sarepta Therapeutics
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
Via Investor's Business Daily
Analyst Ratings For Sarepta Therapeutics
Via Benzinga
Tough Slogging Ahead for Investors, Diversification is Important
Via Talk Markets
Where Sarepta Therapeutics Stands With Analysts
Via Benzinga
Sarepta Therapeutics: Q4 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
Sarepta Therapeutics's Earnings Outlook
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate
Via Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Via Benzinga
Why Sarepta Therapeutics Shares Dropped More Than 16% This Week
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.